medicine-news-1/drinking-your-way-to-health-3f-perhaps-not-59700-2/;msg18067;topicseen

Breaking Biology Technology:Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2 Successful Stem Cell Therapy for Treatment of Eye Disease 2 Successful Stem Cell Therapy for Treatment of Eye Disease 3 Successful Stem Cell Therapy for Treatment of Eye Disease 4 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3 Dendreon Appoints Hans Bishop as Chief Operating Officer 2

[0] Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology [0] Successful Stem Cell Therapy for Treatment of Eye Disease [0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products [0] Dendreon Appoints Hans Bishop as Chief Operating Officer

Breaking Medicine Technology:Within3 Expands into Mobile Applications 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2 Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 1 Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 2 Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 3 New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 1 New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 2 New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 3 Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 1 Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 2

[0] Within3 Expands into Mobile Applications [0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer [0] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program